tiprankstipranks
Trending News
More News >
Mural Oncology Plc (MURA)
NASDAQ:MURA
US Market
Advertisement

Mural Oncology Plc (MURA) Price & Analysis

Compare
437 Followers

MURA Stock Chart & Stats


Bulls Say, Bears Say

Bulls Say
Innovative Treatment PotentialNemvaleukin is a highly differentiated IL-2 fusion protein that blocks adverse event seen from this drug class, stops proliferation of immune dampening T cell types and activates tumor killing NK and T cells.
Positive Outlook For Mucosal MelanomaThe company remains on track for data updates from Phase 2 ARTISTRY-6 in mucosal melanoma, with a focus on positive outcomes.
Potential New OpportunityMural's next catalyst is Phase 2 mucosal melanoma data, potentially providing a new opportunity for success.
Bears Say
Clinical Trial DiscontinuationMURA is discontinuing nemvaleukin's development in platinum-resistant ovarian cancer (PROC).
Missed Primary EndpointA review of the topline data from ARTISTRY-6 cohort showed the primary endpoint was not achieved.
Workforce ReductionThe company will undertake a reduction in its employee workforce of ~90%.

Financials

Ownership Overview

3.32%7.61%<0.01%83.96%
<0.01% Other Institutional Investors
83.96% Public Companies and
Individual Investors

MURA FAQ

What was Mural Oncology Plc’s price range in the past 12 months?
Mural Oncology Plc lowest stock price was $0.95 and its highest was $4.74 in the past 12 months.
    What is Mural Oncology Plc’s market cap?
    Mural Oncology Plc’s market cap is $42.31M.
      When is Mural Oncology Plc’s upcoming earnings report date?
      Mural Oncology Plc’s upcoming earnings report date is Aug 19, 2025 which is in 25 days.
        How were Mural Oncology Plc’s earnings last quarter?
        Mural Oncology Plc released its earnings results on May 14, 2025. The company reported -$1.93 earnings per share for the quarter, beating the consensus estimate of -$1.987 by $0.057.
          Is Mural Oncology Plc overvalued?
          According to Wall Street analysts Mural Oncology Plc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
            Does Mural Oncology Plc pay dividends?
            Mural Oncology Plc does not currently pay dividends.
            What is Mural Oncology Plc’s EPS estimate?
            Mural Oncology Plc’s EPS estimate is -1.
              How many shares outstanding does Mural Oncology Plc have?
              Mural Oncology Plc has 17,268,880 shares outstanding.
                What happened to Mural Oncology Plc’s price movement after its last earnings report?
                Mural Oncology Plc reported an EPS of -$1.93 in its last earnings report, beating expectations of -$1.987. Following the earnings report the stock price went down -3.759%.
                  Which hedge fund is a major shareholder of Mural Oncology Plc?
                  Currently, no hedge funds are holding shares in MURA

                  Company Description

                  Mural Oncology Plc

                  Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Lisata Therapeutics
                  Equillium
                  BioAtla
                  Elevation Oncology
                  Jupiter Neurosciences, Inc.
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis